Kyverna Therapeutics (KYTX) announced the appointment of veteran commercial leader Nadia Dac as chief commercial officer, effective May 4. Dac most recently served as chief commercial officer at Omeros (OMER).
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYTX:
- 3 High-Risk, High-Reward Stocks to Buy Now for Explosive Upside, According to Analysts – 4/23/2026
- Kyverna Therapeutics: Strong CAR‑T Efficacy and Safety in SPS and gMG Underpin Buy Rating and $20 Target
- Kyverna announces strong Phase 2/3 CAR T neuroimmunology data
- Kyverna Reports Positive Phase 2 Data in Stiff Person Syndrome
- Kyverna Therapeutics reports ‘positive’ results from KYSA-8 trial of miv-cel